Olanzapine Fluoxetine Combination (OFC) + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Bipolar Depression
Conditions
Bipolar Depression
Trial Timeline
Apr 1, 2009 โ Feb 1, 2012
NCT ID
NCT00844857About Olanzapine Fluoxetine Combination (OFC) + Placebo
Olanzapine Fluoxetine Combination (OFC) + Placebo is a approved stage product being developed by Eli Lilly for Bipolar Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00844857. Target conditions include Bipolar Depression.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00844857 | Approved | Completed |
Competing Products
20 competing products in Bipolar Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 65 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 77 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 33 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 85 |
| olanzapine + risperidone | Eli Lilly | Approved | 85 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 33 |
| Topiramate + Placebo | Eli Lilly | Approved | 85 |
| olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 52 |